Cigna Group Beheer
Beheer criteriumcontroles 4/4
De CEO Cigna Group is Brian Evanko, benoemd in Mar2025, heeft een ambtstermijn van 1.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.00M, bestaande uit 10.7% salaris en 89.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.024% van de aandelen van het bedrijf, ter waarde $ 17.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 6.8 jaar.
Belangrijke informatie
Brian Evanko
Algemeen directeur
US$10.0m
Totale compensatie
| Percentage CEO-salaris | 10.73% |
| Dienstverband CEO | 1.3yrs |
| Eigendom CEO | 0.02% |
| Management gemiddelde ambtstermijn | 2yrs |
| Gemiddelde ambtstermijn bestuur | 6.8yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 15
CI: PBM Transition Execution And Dividend Strength Will Support Future Share Upside
Analysts have slightly adjusted their price target for Cigna Group, with the fair value estimate moving from about $341.50 to roughly $340.92 as updated assumptions for discount rate, revenue growth, profit margins, and future P/E filter through their models. What's in the News Deutsche Bank and Barclays shifted their views on Cigna Group to more neutral stances, citing multi year uncertainty and risks tied to the pharmacy benefit manager transition, including questions around the insurance portfolio and PBM model.Narratiefupdate • Jun 01
CI: Portfolio Reshaping And CEO Transition Will Support Future Share Upside
Analysts have nudged their price target for Cigna Group slightly higher to about $341.50, reflecting updated assumptions for revenue, profit margins and a modestly higher future P/E multiple. What's in the News Cigna reported Q1 2026 adjusted EPS of US$7.79 on revenue of US$68.5b, above analyst expectations, and raised full year adjusted EPS guidance to at least US$30.35 per share, according to recent earnings coverage.Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking AlphaAnalyseartikel • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...Narratiefupdate • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.Narratiefupdate • Apr 17
CI: Leadership Transition And Buybacks Will Drive Future Upside
Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.Narratiefupdate • Apr 02
CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside
Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.Narratiefupdate • Mar 19
CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.Narratiefupdate • Mar 05
CI: Onsite Care Expansion Will Support Future Upside Potential
Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.Narratiefupdate • Feb 19
CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside
Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.Narratiefupdate • Feb 04
CI: Onsite Clinic And Stable Assumptions Will Support Future Upside
Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.Narratiefupdate • Jan 21
CI: Completed Buybacks And New Employee Clinic Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.Narratiefupdate • Jan 07
CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside
Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.Narratiefupdate • Dec 15
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).Narratiefupdate • Nov 30
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.Narratiefupdate • Nov 16
CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum
Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.Narratiefupdate • Nov 01
CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation
Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.Analyseartikel • Jul 10
The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Seeking Alpha • Mar 31
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Cigna Is A Buy: Market Overreaction Creates A Big Opportunity
Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Cigna: Buy The Drop On This Undervalued Growth Stock
Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Sep 26
Cigna: This Dividend Grower Could Be Worth Buying Now
Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$6b |
| Dec 31 2025 | US$10m | US$1m | US$6b |
| Sep 30 2025 | n/a | n/a | US$6b |
| Jun 30 2025 | n/a | n/a | US$5b |
| Mar 31 2025 | n/a | n/a | US$5b |
| Dec 31 2024 | US$10m | US$994k | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$923k | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$7b |
| Mar 31 2023 | n/a | n/a | US$7b |
| Dec 31 2022 | US$7m | US$837k | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$5b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$5m | US$800k | US$5b |
Compensatie versus markt: De totale vergoeding ($USD 10.00M ) Brian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.47M ).
Compensatie versus inkomsten: De vergoeding van Brian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Brian Evanko (49 yo)
1.3yrs
Tenure
US$9,998,401
Compensatie
Mr. Brian Case Evanko, C.F.A., is President of The Cigna Group from March 2025 and also served as COO Since March 2025 until July 01, 2026 and also serves as CEO Since July 01, 2026 and serves as its Direc...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 16.8yrs | US$22.87m | 0.25% $ 181.5m | |
| President | 1.3yrs | US$10.00m | 0.024% $ 17.8m | |
| Executive VP & CFO | 1.3yrs | US$4.69m | 0.0029% $ 2.1m | |
| Executive Vice President | 2.8yrs | US$5.96m | 0.013% $ 9.4m | |
| Executive Vice President of Strategy & Business Development | 2.5yrs | US$4.07m | 0.0021% $ 1.6m | |
| Senior VP & Tax and Global Chief Accounting Officer | 2yrs | geen gegevens | 0.00090% $ 656.3k | |
| Executive Vice President & Global Chief Information Officer | less than a year | geen gegevens | 0.0025% $ 1.8m | |
| Senior Vice President of Investor Relations | 4.5yrs | geen gegevens | geen gegevens | |
| EVP, General Counsel & Corporate Secretary | less than a year | geen gegevens | geen gegevens | |
| Executive Vice President | less than a year | geen gegevens | geen gegevens | |
| President of International MArkets & President of International Health Cigna Healthcare | 12.1yrs | US$3.53m | geen gegevens | |
| Head of Strategy & Global Business Development for Cigna International Markets | 6.3yrs | geen gegevens | geen gegevens |
2.0yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 16.8yrs | US$22.87m | 0.25% $ 181.5m | |
| President | less than a year | US$10.00m | 0.024% $ 17.8m | |
| Independent Director | 21.4yrs | US$362.81k | 0.00073% $ 532.4k | |
| Lead Independent Director | 15yrs | US$360.31k | 0.014% $ 10.1m | |
| Independent Director | 19.3yrs | US$410.31k | 0.0018% $ 1.3m | |
| Independent Director | 6.1yrs | US$362.81k | 0.0020% $ 1.5m | |
| Independent Director | 7.6yrs | US$360.31k | 0.0026% $ 1.9m | |
| Independent Director | 1.1yrs | US$239.47k | 0.00051% $ 371.9k | |
| Independent Director | 7.6yrs | US$335.31k | 0.0026% $ 1.9m | |
| Independent Director | 3.1yrs | US$335.31k | 0.00098% $ 714.7k | |
| Independent Director | 5.3yrs | US$335.31k | 0.0017% $ 1.3m | |
| Independent Director | 4.8yrs | US$337.81k | 0.0016% $ 1.1m |
6.8yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CI wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/01 21:59 |
| Aandelenkoers aan het einde van de dag | 2026/07/01 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
The Cigna Group wordt gevolgd door 37 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |